Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Buyer insights

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

- PMLiVE

GSK shelves ViiV sale as it lays out growth strategy

Firm now bullish on the HIV joint pharma project’s prospects

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

Choices, choices: the rapidly evolving HIV treatment landscape

The treatment options for HIV in Europe has seen some revolutionary changes

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

- PMLiVE

India turns down patent on Gilead’s Sovaldi

Opens market to cheaper rivals for hepatitis C drug

- PMLiVE

Germany gives green light to Viiv’s Triumeq for HIV

But IQWiG recommendation only covers previously untreated adults

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

First biosimilar Humira launches in India

AbbVie to face competition for world’s biggest-selling drug

Bristol-Myers Squibb (BMS) building

BMS to fund hepatitis projects in China and India

Pharma firm awards nine grants to support care for high-risk patients

- PMLiVE

Ranbaxy hit with EU import ban on antibiotic

Indian generics firm’s plant ruled in breach of manufacturing rules

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links